Tags

Type your tag names separated by a space and hit enter

Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas.
J Biomed Mater Res. 1994 Sep; 28(9):1003-11.JB

Abstract

A bioartificial pancreas, that is, transplantation of islets of Langerhans (islets) which are enclosed in a semipermeable membrane, has been proposed as a treatment for type I diabetes. The islets are immuno-isolated from the host by the semipermeable membrane preventing rejection while maintaining control of glucose metabolism for an extended period. The purpose of the current research is to evaluate the feasibility of preparing agarose microbeads with xenogeneic hamster islets as a bioartificial pancreas in streptozotocin induced diabetic mice. In the recipients with a low level of anti-hamster antibodies, the combination of encapsulation of hamster islets in 5% agarose microbeads and in vitro culture of them prolonged xenograft survivals. Four of 6 recipients were still normoglycemic at 100 days after implantation. However, the same procedure was not effective in the recipients which were sensitized in advance by transplantation of free hamster islets and thus had high levels of anti-hamster antibodies. The average normoglycemic period was 32 days. Antibodies permeated through the microbeads and activated complement on the cell surfaces. The network of agarose microbeads was rendered dense by increasing the concentration of agarose to restrict the diffusion of antibodies. Graft survivals were prolonged with increasing concentrations of agarose. As an analysis using diffusion equations predicted, the survivals were inversely proportional to the diffusion coefficient of IgG in each agarose gel. Islet xenotransplantation was enabled by the combination of the microbeads with a concentration of agarose higher than 7.5% and in vitro culture even in recipients having a high level of preformed antibodies.

Authors+Show Affiliations

Department of Surgical Research, National Cardiovascular Center Research Institute, Osaka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7814428

Citation

Iwata, H, et al. "Feasibility of Agarose Microbeads With Xenogeneic Islets as a Bioartificial Pancreas." Journal of Biomedical Materials Research, vol. 28, no. 9, 1994, pp. 1003-11.
Iwata H, Kobayashi K, Takagi T, et al. Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. J Biomed Mater Res. 1994;28(9):1003-11.
Iwata, H., Kobayashi, K., Takagi, T., Oka, T., Yang, H., Amemiya, H., Tsuji, T., & Ito, F. (1994). Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. Journal of Biomedical Materials Research, 28(9), 1003-11.
Iwata H, et al. Feasibility of Agarose Microbeads With Xenogeneic Islets as a Bioartificial Pancreas. J Biomed Mater Res. 1994;28(9):1003-11. PubMed PMID: 7814428.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. AU - Iwata,H, AU - Kobayashi,K, AU - Takagi,T, AU - Oka,T, AU - Yang,H, AU - Amemiya,H, AU - Tsuji,T, AU - Ito,F, PY - 1994/9/1/pubmed PY - 1994/9/1/medline PY - 1994/9/1/entrez SP - 1003 EP - 11 JF - Journal of biomedical materials research JO - J Biomed Mater Res VL - 28 IS - 9 N2 - A bioartificial pancreas, that is, transplantation of islets of Langerhans (islets) which are enclosed in a semipermeable membrane, has been proposed as a treatment for type I diabetes. The islets are immuno-isolated from the host by the semipermeable membrane preventing rejection while maintaining control of glucose metabolism for an extended period. The purpose of the current research is to evaluate the feasibility of preparing agarose microbeads with xenogeneic hamster islets as a bioartificial pancreas in streptozotocin induced diabetic mice. In the recipients with a low level of anti-hamster antibodies, the combination of encapsulation of hamster islets in 5% agarose microbeads and in vitro culture of them prolonged xenograft survivals. Four of 6 recipients were still normoglycemic at 100 days after implantation. However, the same procedure was not effective in the recipients which were sensitized in advance by transplantation of free hamster islets and thus had high levels of anti-hamster antibodies. The average normoglycemic period was 32 days. Antibodies permeated through the microbeads and activated complement on the cell surfaces. The network of agarose microbeads was rendered dense by increasing the concentration of agarose to restrict the diffusion of antibodies. Graft survivals were prolonged with increasing concentrations of agarose. As an analysis using diffusion equations predicted, the survivals were inversely proportional to the diffusion coefficient of IgG in each agarose gel. Islet xenotransplantation was enabled by the combination of the microbeads with a concentration of agarose higher than 7.5% and in vitro culture even in recipients having a high level of preformed antibodies. SN - 0021-9304 UR - https://www.unboundmedicine.com/medline/citation/7814428/Feasibility_of_agarose_microbeads_with_xenogeneic_islets_as_a_bioartificial_pancreas_ L2 - https://doi.org/10.1002/jbm.820280905 DB - PRIME DP - Unbound Medicine ER -